Bristol-Myers Squibb Company (BMY) |
44.7 -4.16 (-8.51%) 04-25 16:00 |
Open: | 47.39 |
High: | 47.5 |
Low: | 44.37 |
Volume: | 42,293,481 |
Market Cap: | 90,596(M) |
PE Ratio: | 11.58 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 54.48 |
Resistance 1: | 50.62 |
Pivot price: | 49.02 |
Support 1: | 44.37 |
Support 2: | 36.92 |
52w High: | 69.1 |
52w Low: | 44.37 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
EPS | 3.860 |
Book Value | 14.560 |
PEG Ratio | -20.20 |
Gross Profit | 0.000 |
Profit Margin (%) | 17.83 |
Operating Margin (%) | 17.01 |
Return on Assets (ttm) | 5.6 |
Return on Equity (ttm) | 26.5 |
Thu, 25 Apr 2024
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions - Yahoo Finance
Thu, 25 Apr 2024
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Thu, 25 Apr 2024
Why Bristol Myers Squibb Stock Is Sinking Today - Yahoo Finance
Thu, 25 Apr 2024
Why Bristol Myers Squibb Stock Is Sinking Today - The Motley Fool
Thu, 25 Apr 2024
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript - The Motley Fool
Thu, 25 Apr 2024
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts - Barron's
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |